Scandinavian ChemoTech strengthens its working capital through loans of SEK 10 million
The Company has today entered into an agreement to strengthen its working capital by raising a loan from two privately owned companies of a maximum of SEK 10 million. A loan that creates the conditions for the increased market activity and to continue to drive clinical development.The agreement signed today strengthens the Company's finances after previous loans from Erik Penser Bank and an external financier of SEK 5.5 million were repaid during the first quarter of the year. This new credit, which extends to the end of 2021, will lift the Company's financial position and contribute to the